Anesthesiology Doctors in Hamden, CT Accepting Medicare

6 Anesthesiology doctors found. Showing 1 - 6

Hosni Monir Mikhael, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 865 Mix Ave. Apt 507, Hamden, CT 06514 Phone: 203-230-1607    Fax: 203-230-1607

Dr. Giuseppe Capasso, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 18 Glendower Rd, Hamden, CT 06517 Phone: 203-494-7249

Dr. Maria M Messina, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 2200 Whitney Ave, Hamden, CT 06518 Phone: 203-281-3636

Emily Price, Anesthesiology Medicare: Medicare Enrolled Practice Location: 1082 Whitney Ave Fl 3, Hamden, CT 06517 Phone: 513-504-9219

Dr. Mohan Vodapally, M.D.,DABPM Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2447 Whitney Ave, Suite 1, Hamden, CT 06511 Phone: 203-624-4400    Fax: 203-624-4402

Perry Miller, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 121 Blake Rd, Hamden, CT 06517 Phone: 203-787-1888

News Archive

REANIMA project may overturn paradigms that underlie regenerative cardiology research

Research into new endogenous mechanisms of tissue regeneration is an innovative research avenue in cardiac regeneration.

Folic acid can dramatically reduce the incidence of spina bifida and other birth defects

A study, published today in BMC Pregnancy and Childbirth, shows that the proportion of babies born with neural tube defects in the province of Newfoundland and Labrador dropped by 78% after the Canadian Government directed that folic acid must be added to flour, cornmeal and pasta. The study supports the continuation of this food fortification strategy.

FDA grants first cervical multilevel indication to Centinel Spine's STALIF C integrated interbody device

Centinel Spine, Inc., the pioneer of Stand-Alone, No-Profile, Integrated Interbody fusion devices was granted the first cervical multilevel indication for a Stand-Alone interbody device by the U.S. Food and Drug Administration (FDA).

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

Read more Medical News

› Verified 4 days ago